Methods and compositions for tissue regeneration
View Patent ↗A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, IL-6, IL-8, TGFα, and TNFα, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.
1. A cell preparation comprising mitotically inactive allogeneic cells that are capable of secreting one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-1β, IL-6, IL-8, TGFα, and TNFα, wherein the cells are keratinocytes or fibroblasts, or mixtures thereof, and wherein the cell preparation is comprised in a buffered solution, a wound dressing, or an extracellular matrix or matrix material.
2. The cell preparation of claim 1 , wherein the cells are mitotically inactivated by irradiation.
3. The cell preparation of claim 1 , wherein the cells are differentiated.
4. The cell preparation of claim 1 , wherein the concentration of cells are in the range of about 1×10 3 cells/μl to about 50×10 3 cells/μl.
5. The cell preparation of claim 1 , wherein the cells are a mixture of keratinocytes and fibroblasts and the ratio of keratinocytes to fibroblasts is 1:9.
6. The cell preparation of claim 1 , wherein the cell preparation is comprised in a buffered solution.
7. The cell preparation of claim 6 , wherein the buffered solution is HBSS.
8. The cell preparation of claim 7 , wherein the HBSS comprises Ca ++ and Mg ++ .
9. The cell preparation of claim 1 , wherein the cell preparation is comprised in a wound dressing.
10. The cell preparation of claim 1 , wherein the cell preparation is comprised in an extracellular matrix or matrix material.
11. The cell preparation of claim 1 , wherein the cell preparation is in the form of a paste.
12. The cell preparation of claim 1 , wherein the cell preparation is in the form of a spray.
13. The cell preparation of claim 1 , further comprising a cryoprotectant.
14. The cell preparation of claim 13 , wherein the cell preparation is cryopreserved.
15. The cell preparation of claim 1 , wherein the cell preparation is comprised in a container.
16. The cell preparation of claim 1 , wherein the cell preparation is comprised in a sterile vial.
17. A cell preparation comprising mitotically inactive allogeneic cells that are capable of secreting one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, IL-6, IL-8, TGFα, and TNFα, wherein the cells are keratinocytes or fibroblasts, or mixtures thereof, and wherein the cell preparation is in the form of a paste or spray.
18. The cell preparation of claim 17 , wherein the cells are mitotically inactivated by irradiation.
19. The cell preparation of claim 17 , wherein the cells are differentiated.
20. The cell preparation of claim 17 , wherein the concentration of cells are in the range of about 1×10 3 cells/μl to about 50×10 3 cells/μl.
21. The cell preparation of claim 17 , wherein the cells are a mixture of keratinocytes and fibroblasts and the ratio of keratinocytes to fibroblasts is 1:9.
22. The cell preparation of claim 17 , wherein the cell preparation is in the form of a paste.
23. The cell preparation of claim 17 , wherein the cell preparation is in the form of a spray.
24. A cell preparation comprising mitotically inactive allogeneic cells that are capable of secreting one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, IL-6, IL-8, TGFα, and TNFα, wherein the cells are a mixture of keratinocytes and fibroblasts and the ratio of keratinocytes to fibroblasts is 1:9.
25. The cell preparation of claim 24 , wherein the cells are mitotically inactivated by irradiation.
26. The cell preparation of claim 24 , wherein the cells are differentiated.
27. The cell preparation of claim 24 , wherein the concentration of cells are in the range of about 1×10 3 cells/μl to about 50×10 3 cells/μl.
28. The cell preparation of claim 24 , wherein the cell preparation is comprised within a biologically acceptable carrier.
29. A cell preparation comprising mitotically inactive allogeneic cells that are capable of secreting one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, IL-6, IL-8, TGFα, and TNFα, wherein the cells are keratinocytes or fibroblasts, or mixtures thereof, and wherein the cell preparation further comprises a cryoprotectant.
30. The cell preparation of claim 29 , wherein the cells are mitotically inactivated by irradiation.
31. The cell preparation of claim 29 , wherein the cells are differentiated.
32. The cell preparation of claim 29 , wherein the concentration of cells are in the range of about 1×10 3 cells/μl to about 50×10 3 cells/μl.
33. The cell preparation of claim 29 , wherein the cell preparation is cryopreserved.
34. The cell preparation of claim 29 , wherein the cell preparation is comprised within a biologically acceptable carrier.